BD (NYSE: BDX) recently issued a medical device correction later related to its Bard subsidiary's Rotarex atherectomy system.

Functional recovery at 90 days was lower in the balloon-guided catheter group versus the conventional catheter group. 2.

The FDA is getting the word out on a high-risk issue related to artery-clearing catheters from BD’s Bard Peripheral Vascular ...

At the University of Minnesota's heart lab, millions of dollars of tubing and wires and technology work to keep a living ...

By combining MERFISH imaging with expansion microscopy, researchers have unlocked a new way to study bacteria at the ...

The most common symptoms I hear from my patients are leg cramping or discomfort with walking. They often tell me they can ...

Teleflex Incorporated (NYSE:TFX – Free Report) by 7.4% in the 4th quarter, according to its most recent Form 13F filing with ...

The FDA labeled a recall of integrated arterial catheters made by Medline Class I, the most serious kind of recall.

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

David Duncan, a meticulous retired judge, led an inquest into Arizona's execution protocols -- until it was subverted by ...

The CVC market is projected to grow from USD 2,861.0 million in 2024 to USD 5,436.8 million by 2034 at a CAGR of 6.6%.